Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alaxan is an over-the-counter (OTC) fixed-dose combination analgesic developed and marketed by United International Pharma. It contains two active ingredients: Paracetamol (325 mg) and Ibuprofen (200 mg). Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system and elevating the pain threshold. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that provides anti-inflammatory, analgesic, and antipyretic effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins. Alaxan is primarily indicated for the management of mild to moderate musculoskeletal pain, including back pain, neck strain, sprains, and rheumatism, as well as headache, toothache, and menstrual pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alaxan.